Company Overview

Par Drugs and Chemicals Limited is an India-based company primarily engaged in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) for both domestic and international markets. The company also produces a range of antacid molecules. Incorporated in 1982, Par Drugs & Chemicals Ltd manufactures APIs and Fine Chemicals, establishing itself as a notable player in the pharmaceutical ingredients sector.

Par Drugs and Chemicals Limited was originally incorporated as "Par Drugs and Chemicals Private Limited" in Bhavnagar, Gujarat. On 26 February 1999, it was converted into a Public Limited Company and renamed "Par Drugs and Chemicals Limited" on 5 November 2018. The Company raised funds from the public through an IPO, issuing 16,72,000 Equity Shares aggregating to ₹8.53 Crore in May 2019.

Manufacturing Infrastructure and Product Portfolio

The company operates from strategically located manufacturing facilities in Gujarat. Par Drugs & Chemicals Ltd currently owns and operates two manufacturing facilities at Bhavnagar and Ankleshwar in Gujarat. It has three manufacturing blocks at the Bhavnagar facility dedicated to different products. The Bhavnagar facility is certified by the Food & Drugs Control Administration. In 2011, the company added two manufacturing blocks to its Chitra, Bhavnagar facility: one dedicated to its main APIs and another for Fine Chemicals.

PACL (Par Drugs & Chemicals Ltd) manufactures Active Pharmaceutical Ingredients for domestic and export markets. Their initial portfolio comprised 15 APIs and 10 Fine Chemicals. The product portfolio has since diversified and currently includes 12 APIs and 6 Fine Chemicals that are marketed domestically and exported. This comprehensive portfolio positions the company well to serve various pharmaceutical companies across different therapeutic segments.

Market Presence and Customer Base

Par Drugs & Chemicals has established a strong presence in both domestic and international markets. The Company supplies its products to approximately 16 countries, through both direct and indirect exports. Key customers include Essential Drugs Company Limited, Taurus Chemicals (P) Limited, Pfizer Limited, United Phosphorus Limited (Samba Jammu Unit), and Shiv Silica Private Limited. This diversified customer base, including major pharmaceutical giants, demonstrates the company's reliability and quality standards in the industry.

Financial Performance and Market Capitalization

As of the latest available data, Par Drugs & Chemicals Ltd has a market capitalization of ₹124 Crore.

The company's financial performance shows mixed results across different periods:

- Quarter Ended September 2024: Net profit rose 75.87% to ₹8.60 Crore compared to ₹4.89 Crore in the quarter ended September 2023. Sales increased by 33.87% to ₹34.66 Crore from ₹25.89 Crore in the same period.

- Quarter Ended December 2024: Net profit declined 83.04% to ₹0.58 Crore compared to ₹3.42 Crore in the previous year's quarter. Sales decreased by 10.92% to ₹21.38 Crore from ₹24.00 Crore in Q3 FY2023-24.

Annual Financial Metrics (Trailing 12 Months - FY25)

- Operating Revenue: ₹100.97 Crore

- Annual Revenue Growth: 8%

- Pre-Tax Margin: 18%

- Return on Equity (ROE): 13%

- Profit After Tax (TTM): ₹13 Crore

Stock Valuation and Key Ratios

The stock's valuation metrics present an interesting investment proposition:

- Current PE Ratio: 9.31

- Current PB Ratio: 1.26

- 52-Week High: ₹348.45

- 52-Week Low: ₹81.01

Financial Strength and Capital Structure

One of the company's notable strengths is its debt-free status. Par Drugs & Chemicals Ltd maintains a strong balance sheet, enabling it to report stable earnings growth across business cycles. This positions the company favorably in terms of financial flexibility and reduces financial risk.

Regarding the shareholding pattern, Promoter holding in Par Drugs & Chemicals Ltd has slightly decreased to 73.37% as of March 2025 from 74.21% in the previous period, indicating a minor dilution in promoter stake while maintaining substantial control.

Management and Leadership

Key management personnel include:

- Chairman: FALGUN VALLABHBHAI SAVANI

- Company Secretary: Sanket Bhupendrabhai Trivedi

The promoters of Par Drugs & Chemicals Ltd are FALGUN VALLABHBHAI SAVANI, JIGNESHBHAI VALLABHBHAI SAVANI, Krishna Mitulbhai Shah, Kajal Chintanbhai Vaghani, Pravin Manjibhai Bhayani, Bintal Bhaveshkumar Shah, and Sanket Bhupendrabhai Trivedi.

Industry Position and Competitive Landscape

Par Drugs and Chemicals Ltd (PAR) belongs to the Health Care sector and the Pharmaceuticals sub-sector. Its peers include major players like Sun Pharmaceutical Industries Ltd, Divi's Laboratories Ltd, Cipla Ltd, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Dr. Reddy's Laboratories Ltd, and Zydus Lifesciences Ltd. While competing against pharmaceutical giants, the company has carved out its niche in the API manufacturing segment.

The company's recent financial results reflect both opportunities and challenges within the pharmaceutical sector. Despite quarterly volatility, Par Drugs & Chemicals' debt-free status, established manufacturing capabilities, and diversified product portfolio provide a solid foundation for future growth. Investors should consider the company's strong balance sheet position against the backdrop of quarterly earnings fluctuations when evaluating this mid-cap pharmaceutical stock.